Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | KMO | O15229 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731073 | 0.84 | CYP1A2 (0.62) | RECQLCYP1A2KMOADRA2ADAO | |
| SCHEMBL731911 | 0.81 | CYP1A2 (0.58) | RECQLCYP1A2KMOADRA2ADAO | |
| SCHEMBL7331551 | 0.81 | RECQL (0.69) | RECQLCYP1A2KMOADRA2ADAO | |
| SCHEMBL29520910 | 0.79 | RECQL (0.61) | RECQLCYP1A2KMOADRA2ADAO | |
| SCHEMBL3076519 | 0.79 | RECQL (0.61) | RECQLCYP1A2KMOADRA2ADAO | |
| SCHEMBL29520779 | 0.79 | RECQL (0.61) | RECQLCYP1A2KMOADRA2ADAO | |
| SCHEMBL13217 | 0.79 | RECQL (0.61) | RECQLCYP1A2KMOADRA2ADAO | |
| SCHEMBL9934408 | 0.79 | RECQL (0.61) | RECQLCYP1A2KMOADRA2ADAO | |
| SCHEMBL9934410 | 0.79 | RECQL (0.61) | RECQLCYP1A2KMOADRA2ADAO | |
| SCHEMBL6125449 | 0.79 | RECQL (0.61) | RECQLCYP1A2KMOADRA2ADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894396-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-10-20 | — | — | EP | claimed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | claimed |
| CN-102112449-A | Phenyl or pyridinyl substituted indazoles derivatives | ASTRAZENECA AB | 2011-06-29 | — | — | CN | claimed |
| EP-2291359-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20100080786-A1 | Phenyl or Pyridinyl Substituted Indazoles Derivatives | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | claimed |
| WO-2009142569-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4351570-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347569-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| CN-117715893-A | Combination therapy comprising a MAT2A inhibitor and a PRMT type II inhibitor | 伊迪亚生物科学公司 | 2024-03-15 | — | — | CN | disclosed |
| US-4009177-A | Compound 2-(2-thiazolyl)-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-4009177-A | Compound 2-(2-thiazolyl)-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-4002652-A | 2-Substituted-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-01-11 | — | — | US | disclosed |
| US-4002652-A | 2-Substituted-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-01-11 | — | — | US | disclosed |
| US-3966760-A | 2-Substituted-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966760-A | 2-Substituted-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | RECQL 1388/4885CYP1A2 3409/4885KMO 2836/4885 |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | RECQL 1388/4885CYP1A2 3409/4885KMO 2836/4885 |
| US-20100080786-A1 | Phenyl or Pyridinyl Substituted Indazoles Derivatives | CYP3A5, CYP3A43, ABCB1 | RECQL 646/4885CYP1A2 12/4885KMO 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.